Use of factor-VII-rich prothrombin complex concentrate in liver disease.
A prothrombin complex concentrate rich in factor VII has been used in the management of the clotting defect in thirteen patients with liver disease. Adequate correction of coagulation was achieved immediately after infusion in all cases. Within 4 hours there was some deterioration and by 24 hours the results approximated to pre-fusion values. Liver biopsies were performed without haemorrhagic complication in the immediate post-infusion period. There was no evidence of induced intravascular coagulation. Since other prothrombin complex concentrates have proved disappointing, both in their failure to correct the clotting defect and in their production of disseminated intravascular coagulation, this factor-VII-rich concentrate may be the treatment of choice in patients with liver disease who require temporary correction of their coagulation defect.
D001778:Blood Coagulation Disorders / Q000209:etiology / Q000628:therapy*; D001780:Blood Coagulation Tests; D005165:Factor V / Q000032:analysis; D005167:Factor VII / Q000032:analysis / Q000627:therapeutic use*; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D007263:Infusions, Parenteral; D008107:Liver Diseases / Q000150:complications*; D010714:Phosphatidylethanolamines / Q000032:analysis; D011516:Prothrombin / Q000008:administration & dosage / Q000627:therapeutic use*; D013917:Thrombin / Q000032:analysis; D013997:Time Factors
D010714:Phosphatidylethanolamines; D005165:Factor V; D005167:Factor VII; D011516:Prothrombin; D005340:Fibrinogen; D013917:Thrombin